SNY
Sanofi
NASDAQ · Healthcare · Drug Manufacturers - General · FR
$44.24
−0.20%Year over year
Reported trailing growth
- Revenue
- +13.4%
- EBITDA
- +31.1%
- EBIT
- -8.6%
- EPS
- -87.5%
- Free cash flow
- +462.3%
- Operating cash flow
- +582.9%
Forward estimates
Based on analyst estimates
- Revenue
- -47.6%
- EBITDA
- -36.8%
- EPS
- +388.3%
Three-year CAGR
- Revenue
- +4.8%
- EBITDA
- -2.6%
- EBIT
- -1.9%
- Net income
- -2.3%
- EPS
- +0.1%
- Free cash flow
- +6.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026